Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Gastrointestinal Motility Disorders

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026

Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.

Nature communications·2026

Same author

SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST).

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.

Future oncology (London, England)·2025

Same author

Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration.

Journal of immunotherapy and precision oncology·2025

Same journal

Genetics-Supported Mainstream Testing Improves Access and Efficiency for Patients With Breast Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 28, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Gastrointestinal stromal tumors, version 2.2014.

Margaret von Mehren¹, R Lor Randall¹, Robert S Benjamin¹

¹From Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; The University of Texas MD Anderson Cancer Center; UC San Diego Moores Cancer Center; Moffitt Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Roswell Park Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; UCSF Helen Diller Family Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; City of Hope Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and National Comprehensive Cancer Network.

Journal of the National Comprehensive Cancer Network : JNCCN

|June 14, 2014

Summary

This summary is machine-generated.

Gastrointestinal stromal tumors (GIST) management is updated for patients progressing on imatinib or sunitinib. NCCN Guidelines provide insights for these challenging soft tissue sarcoma cases.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

Published on: February 19, 2022

Related Experiment Videos

Last Updated: Apr 28, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

Published on: February 19, 2022

Area of Science:

Oncology
Gastrointestinal Oncology
Sarcoma Research

Background:

Gastrointestinal stromal tumors (GIST) are the most common gastrointestinal soft tissue sarcomas.
GIST pathogenesis frequently involves KIT or platelet-derived growth factor receptor α (PDGFRα) activating mutations.
Disease progression on imatinib and/or sunitinib presents a significant clinical challenge in GIST management.

Framework:

NCCN Guideline Insights provide updated recommendations.
Focus on managing patients with advanced GIST.
Addresses treatment after failure of standard tyrosine kinase inhibitors.

Implementation:

Highlights critical updates to the NCCN Guidelines for Soft Tissue Sarcoma.
Provides a framework for clinical decision-making in GIST progression.
Aims to optimize patient outcomes through guideline adherence.

Implications:

Improved management strategies for GIST patients with acquired resistance.
Potential for enhanced therapeutic efficacy in refractory GIST.
Advances the standard of care for soft tissue sarcoma treatment.